Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Lichtenberg

Showing results (41-50 of 92) with videos related to

Pageof 10
Sort By:
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 7, 2015
The impact of pharmaceutical innovation on premature cancer mortality in Switzerland, 1995-2012Frank R Lichtenberg
The American Economic Review|April 7, 1996
Do (more and better) drugs keep people out of hospitals?F R Lichtenberg
Forum for Health Economics & Policy|April 25, 2019
The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects AnalysisFrank R Lichtenberg
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 29, 2011
The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999-2007Frank R Lichtenberg
Expert Review of Pharmacoeconomics & Outcomes Research|January 8, 2020
How cost-effective are new cancer drugs in the U.S.?Frank R Lichtenberg
Economics and Human Biology|October 7, 2004
The effect of new drug approvals on HIV mortality in the US, 1987-1998Frank R Lichtenberg
Economics and Human Biology|May 14, 2013
The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000-2009Frank R Lichtenberg
Public Health|November 19, 2020
Are estimates of 'potential gains in life expectancy' potentially unreliable?F R Lichtenberg
The Journal of Medicine and Philosophy|January 7, 2006
Pharmaceutical innovation and the burden of disease in developing and developed countriesFrank R Lichtenberg
Forum for Health Economics & Policy|August 18, 2019
The Impact of Pharmaceutical Innovation on Cancer Mortality in Belgium, 2004-2012Frank R Lichtenberg
Pageof 10

Showing results (41-50 of 92) with videos related to

Sort By:
Pageof 10
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 7, 2015
The impact of pharmaceutical innovation on premature cancer mortality in Switzerland, 1995-2012Frank R Lichtenberg
The American Economic Review|April 7, 1996
Do (more and better) drugs keep people out of hospitals?F R Lichtenberg
Forum for Health Economics & Policy|April 25, 2019
The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects AnalysisFrank R Lichtenberg
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 29, 2011
The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999-2007Frank R Lichtenberg
Expert Review of Pharmacoeconomics & Outcomes Research|January 8, 2020
How cost-effective are new cancer drugs in the U.S.?Frank R Lichtenberg
Economics and Human Biology|October 7, 2004
The effect of new drug approvals on HIV mortality in the US, 1987-1998Frank R Lichtenberg
Economics and Human Biology|May 14, 2013
The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000-2009Frank R Lichtenberg
Public Health|November 19, 2020
Are estimates of 'potential gains in life expectancy' potentially unreliable?F R Lichtenberg
The Journal of Medicine and Philosophy|January 7, 2006
Pharmaceutical innovation and the burden of disease in developing and developed countriesFrank R Lichtenberg
Forum for Health Economics & Policy|August 18, 2019
The Impact of Pharmaceutical Innovation on Cancer Mortality in Belgium, 2004-2012Frank R Lichtenberg
Pageof 10